Issue 10, 2026, Issue in Progress
From the journal:

RSC Advances

Correction: Evaluating the therapeutic efficacy of gastramide theranostics targeting cholecystokinin-2 receptors in a preclinical setting

Marwa N. Rahimi,ab   Jo-Anne Pinson,ab   Joseph Hilton-Proctor,ab   Jessica Van Zuylekom,bc   Benjamin Blyth,bc   Peter D. Roseltab  and  Mohammad B. Haskali*ab  

* Corresponding authors

a Department of Radiopharmaceutical Sciences, Cancer Imaging, The Peter MacCallum Cancer Centre, Victoria 3000, Australia
E-mail: mo.haskali@petermac.org

b Sir Peter MacCallum Department of Oncology, The University of Melbourne, Victoria 3010, Australia

c Models of Cancer Translational Research Centre, The Peter MacCallum Cancer Centre, Victoria 3000, Australia

Abstract

Correction for ‘Evaluating the therapeutic efficacy of gastramide theranostics targeting cholecystokinin-2 receptors in a preclinical setting’ by Marwa N. Rahimi et al., RSC Adv., 2026, 16, 2123–2132, https://doi.org/10.1039/D5RA08789A.

About
Cited by
Related
Download options Please wait...

Associated articles

Article information

DOI
https://doi.org/10.1039/D6RA90008A
Article type
Correction
Submitted
23 Jan 2026
Accepted
23 Jan 2026
First published
12 Feb 2026
This article is Open Access
Creative Commons BY license

RSC Adv., 2026,16, 8693-8694

Permissions

Request permissions

Correction: Evaluating the therapeutic efficacy of gastramide theranostics targeting cholecystokinin-2 receptors in a preclinical setting

M. N. Rahimi, J. Pinson, J. Hilton-Proctor, J. Van Zuylekom, B. Blyth, P. D. Roselt and M. B. Haskali, RSC Adv., 2026, 16, 8693 DOI: 10.1039/D6RA90008A

This article is licensed under a Creative Commons Attribution 3.0 Unported Licence. You can use material from this article in other publications without requesting further permissions from the RSC, provided that the correct acknowledgement is given.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements